Kellerhals Carrard, under the responsibility of partners Dr. Claudia Götz Staehelin, Dr. Oliver M. Brupbacher and Dr. Nicolas Mosimann, advised Moderna on legal and regulatory aspects related to the establishment of its supply chain for its COVID-19 Vaccine and Swiss launch preparations, including trade compliance and regulatory aspects.

Moderna is pioneering a new class of drugs, the messenger RNA Therapeutics (mRNAs), with the potential to treat a wide range of diseases and conditions. Moderna developed a vaccine against COVID-19 for which Swissmedic granted a temporary marketing authorization on 12 January 2021 under the name „COVID-19 Vaccine Moderna" following the scientific assessment of Swissmedic.